Labcorp reaffirmed its 2026 targets and outlined a constructive, multi-year growth trajectory, including 5-8% revenue CAGR and 8.5-11.5% EPS CAGR through 2029. The plan emphasizes specialty testing, stronger health-system partnerships, personalized health solutions, and AI/robotics integration. Despite beating guidance, shares declined about 3.7% on the day, signaling mixed short-term reception to the long-term roadmap.
Labcorp reported stronger-than-expected Q2 results and raised its full-year profit forecast, driven by steady diagnostic-testing demand and growth in its drug-development services (CDMO) segment. The print underscores resilience in core lab operations and a higher-margin CDMO mix, potentially supporting earnings upside and multiple expansion if demand remains durable.
Labcorp Holdings reported a solid Q1 with earnings of $4.25, exceeding analysts' forecasts. The company also raised its full-year EPS guidance, reflecting confidence driven by technology investments aimed at improving operational efficiency.
Labcorp announced an increase in its full-year profit and revenue forecasts after exceeding quarterly expectations, driven by steady demand for diagnostic testing. This development signals growing confidence in the diagnostics sector, likely attracting investor interest and positively impacting Labcorp’s stock price in the near term.
Labcorp's recent forecast indicates an annual profit above Wall Street estimates, driven by robust demand for its diagnostic tests. This positive outlook could lead to increased investor confidence in the company's growth potential, likely supporting its stock price in the near term.
